PMID- 26881769
OWN - NLM
STAT- MEDLINE
DCOM- 20160503
LR  - 20191210
IS  - 2159-3000 (Print)
IS  - 2159-3000 (Linking)
VI  - 441
DP  - 2016 Feb
TI  - The Changing Drug Culture: Emerging Drugs of Abuse and Legal Highs.
PG  - 18-24
AB  - In recent years, there has been a large increase in the number of synthetic drugs 
      used recreationally. One class of drugs is synthetic cannabinoids, which are 
      sprayed onto herbal preparations and marketed under names such as K2 and spice. 
      Others include amphetaminelike compounds, such as cathinones (eg, bath salts) and 
      methylenedioxymethamphetamine (MDMA) (eg, ecstasy, Molly). New hallucinogens, 
      such as Bromo-Dragonfly, and hallucinogens that have been used for centuries, 
      such as Salvia divinorum, also are gaining popularity. Because these substances 
      are sold labeled as not for human consumption and because the chemicals in them 
      frequently change, they often are unregulated, and many users consider them 
      legal, although they are not. Their use often goes undetected because testing for 
      them is not included in routine drug screening. Nonetheless, these substances can 
      be associated with significant toxicities, often because their concentrations are 
      unpredictable. Adverse effects of synthetic cannabinoids include psychosis and 
      other effects. Amphetaminelike drugs have stimulant effects and can cause 
      hyponatremia and seizures. The new hallucinogens can cause serious 
      vasoconstriction with ischemia. Clinicians, especially those working with 
      adolescents and young adults (ie, the main users of these drugs), should be aware 
      of these new substances and counsel patients about their adverse effects.
CI  - Written permission from the American Academy of Family Physicians is required for 
      reproduction of this material in whole or in part in any form or medium.
FAU - Albertson, Timothy E
AU  - Albertson TE
AD  - UC Davis Medical Center Patient Support Services Building, 4150 V Street Suite 
      3100, Sacramento, CA 95817.
FAU - Chenoweth, James A
AU  - Chenoweth JA
AD  - UC Davis Medical Center Patient Support Services Building, 4150 V Street Suite 
      3100, Sacramento, CA 95817.
FAU - Colby, Daniel K
AU  - Colby DK
AD  - UC Davis Medical Center Patient Support Services Building, 4150 V Street Suite 
      3100, Sacramento, CA 95817.
FAU - Sutter, Mark E
AU  - Sutter ME
AD  - UC Davis Medical Center Patient Support Services Building, 4150 V Street Suite 
      3100, Sacramento, CA 95817.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - FP Essent
JT  - FP essentials
JID - 101578821
RN  - 0 (Amphetamines)
RN  - 0 (Cannabinoids)
RN  - 0 (Illicit Drugs)
SB  - IM
MH  - Amphetamines/adverse effects/pharmacology
MH  - Automobile Driving
MH  - Cannabinoids/adverse effects/pharmacology
MH  - *Culture
MH  - Drug Overdose/physiopathology
MH  - Drug and Narcotic Control
MH  - Humans
MH  - Illicit Drugs/*adverse effects/*pharmacology
MH  - Substance Abuse Detection
MH  - Substance Withdrawal Syndrome/physiopathology
MH  - Substance-Related Disorders/*complications
EDAT- 2016/02/18 06:00
MHDA- 2016/05/04 06:00
CRDT- 2016/02/17 06:00
PHST- 2016/02/17 06:00 [entrez]
PHST- 2016/02/18 06:00 [pubmed]
PHST- 2016/05/04 06:00 [medline]
PST - ppublish
SO  - FP Essent. 2016 Feb;441:18-24.